Tyson Foods, COMSCORE, Aratana Therapeutics Stocks Moving Today

TSN, SCOR, and PETX are among the stocks on the move today

Feb 6, 2017 at 2:01 PM
facebook twitter linkedin


U.S. stocks are treading water this afternoon. Among specific equities in focus today are chicken producer Tyson Foods, Inc. (NYSE:TSN), data specialist COMSCORE, Inc. (NASDAQ:SCOR), and veterinary drug stock Aratana Therapeutics Inc (NASDAQ:PETX). Here's a quick look at what's moving shares of TSN, SCOR, and PETX.

SEC Subpoena Overshadows Tyson Foods Earnings Beat

TSN was last seen 3.5% lower at $63.11, as news of a subpoena from the Securities and Exchange Commission (SEC) takes precedent over the company's earnings beat. The company believes the subpoena is connected to price-fixing allegations. Looking back, the shares have now shed 18.1% since their all-time high of $77.05 from early September, and bullish analysts may be wondering if it's time to rethink their positions. At the moment, five of seven brokerage firms rate Tyson Foods, Inc. a "strong buy," with zero "sell" ratings to be found. 

COMSCORE Tanks Amid Delisting Chatter

SCOR is the biggest loser on the Nasdaq today, down 26% at $24 -- and earning a sport on the short-sale restricted list -- after the company said it will not be able to meet a Feb. 23 deadline for restating past financial results, and could be delisted (subscription required) from the exchange as a result. The shares were already well below their February annual peak of $43.53 coming into today, and are now on pace for their lowest close since late June. Short sellers, meanwhile, are probably racking up gains with their bearish positions on COMSCORE, Inc. Short interest has increased 84% since mid-August, putting over 15% of the stock's float in the hands of short sellers. 

FDA Request Bites Aratana Therapeutics

PETX is also hurting today, down 18.4% at $6.56, after the Food and Drug Administration (FDA) requested additional information on the company's new manufacturing partner for Entyce, an appetite stimulant for dogs. The request will delay the launch of Entyce to late 2017. Aratana Therapeutics Inc is set to close below its 50-week moving average for the first time since July, which should be good news for the few options traders that have targeted the stock. Specifically, put open interest on PETX currently sits at a 52-week high, albeit on light absolute levels.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earnings guide for Q3 before it's too late!


  
 
Special Offers from Schaeffer's Trading Partners